CERo Therapeutics Holdings - Warrants (13/02/2029) Net Income

As of the most recent data (June 2026), CEROW shows a net income of $-130M. That compares with $-17M in the prior-year period — down 653.0% year over year. That is below the sector sector average of $89M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CEROW's net income is now $-130M (was $-17M) — a 653.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CERo Therapeutics Holdings - Warrants (13/02/2029) is outperforming or lagging.

The its sector sector average net income is about $89M. CERo Therapeutics Holdings - Warrants (13/02/2029) is at $-130M, which is lower that average. That is roughly 242.8% below the sector mean. Use the comparison chart on this page to see how CEROW stacks up against individual peers as well.

Tracking CEROW's net income over time shows whether CERo Therapeutics Holdings - Warrants (13/02/2029) is scaling, shrinking, or reshaping that part of the business. The current reading is $-130M That compares with $-17M in the prior-year period — down 653.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has CERo Therapeutics Holdings - Warrants (13/02/2029)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-130M) with ownership activity and broader fundamentals.